Matthew Reynolds to Drug-Eluting Stents
This is a "connection" page, showing publications Matthew Reynolds has written about Drug-Eluting Stents.
Connection Strength
0.659
-
Reynolds MR, Pinto DS, Shi C, Walczak J, Berezin R, Holmes DR, Cohen DJ. Cost-effectiveness of sirolimus-eluting stents compared with vascular brachytherapy for the treatment of in-stent restenosis. Am Heart J. 2007 Dec; 154(6):1221-7.
Score: 0.259
-
Reynolds MR, Gong T, Li S, Herzog CA, Charytan DM. Cost-Effectiveness of Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease and Acute Coronary Syndromes in the US Medicare Program. J Am Heart Assoc. 2021 04 06; 10(7):e019391.
Score: 0.166
-
Galper BZ, Reynolds MR, Garg P, Secemsky EA, Valsdottir LR, Cohen DJ, Yeh RW. Cost-effectiveness analysis of short-duration dual antiplatelet therapy with newer drug-eluting stent platforms versus longer-duration dual antiplatelet therapy with a second-generation drug-eluting stent in elective percutaneous coronary intervention. Coron Artery Dis. 2019 05; 30(3):177-182.
Score: 0.145
-
Amin AP, Reynolds MR, Lei Y, Magnuson EA, Vilain K, Durtschi AJ, Simonton CA, Stone GW, Cohen DJ. Cost-effectiveness of everolimus- versus paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization (from the SPIRIT-IV Trial). Am J Cardiol. 2012 Sep 15; 110(6):765-70.
Score: 0.090